Study design
ADAPT was a randomized, double-blind, placebo-controlled, multicenter, phase 3 study [The ADAPT study was conducted according to the International Conference on Harmonisation Guideline for Good Clinical Practice, the principles of the Declaration of Helsinki, and other applicable local ethical and legal requirements. Independent ethics committees and international review boards provided written approval for the study protocol and all amendments. The ADAPT study was sponsored by argenx (Ghent, Belgium).